At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...

In 2022, pharmaceutical giant Pfizer (NYSE: PFE) became the first healthcare company to generate $100 billion in annual sales ...

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

resource that aims to "improve health equity and advance personalised medicine." Pfizer is the first big pharma company to sign up to make use of the platform, which used machine learning and ...

Pfizer targets $4 billion in operational savings ... molecular profiles (a trend increasingly favored in precision medicine). In short, the pipeline diversity here enables near-term commercial ...

Sangamo faces steep drop after Pfizer ends partnership, raising concerns about its hemophilia therapy's future ...

Charlotte Allerton, Pfizer's head of medicine design, said: "The XtalPi collaboration is an opportunity to enhance our computational modelling capabilities. "We are looking forward to potentially ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

President Trump has vowed to impose tariffs on China, Mexico, and Canada. They could make common medicines less affordable.

Oklahoma City Indian Clinic announced it has received a $250,000 charitable contribution from Pfizer to support programs ...